Abstract
The present study tested the effects of valsartan, an angiotensin II receptor blocker, on the progression of renal insufficiency in patients with nondiabetic renal diseases. The study subjects were 22 patients with nondiabetic renal diseases whose serum creatinine (Cr) ranged from 1.5 to 3.0 mg/dl. Valsartan (40–80 mg) or placebo was given once daily for 1 year each in a random crossover manner. In both periods, antihypertensive medications were titrated when the blood pressure was not lower than 140/90 mmHg. Blood sampling and urinalysis were performed bimonthly throughout the study periods. The average blood pressure was comparable between the valsartan and the placebo periods (130±9/86 ±6 vs. 131±8/86±6 mmHg). Serum Cr significantly increased from 1.9±0.5 to 2.3±0.8 mg/dl (p<0.001) during the placebo period, but the change was insignificant in the valsartan period (2.1±0.6 to 2.2±0.9 mg/dl). The slope of decrease in the reciprocal of serum Cr was steeper in the placebo period than in the valsartan period (−0.064 ±0.070/year vs. −0.005±0.050/year, p<0.01). During the valsartan period, urinary protein excretion was less than that during the placebo period (0.75±0.73 vs. 1.24±0.92 g/g Cr, p<0.001). Serum K was significantly higher in the valsartan period than in the placebo period (4.6±0.5 vs. 4.4±0.5 mEq/l, p<0.05); however, no patients discontinued taking valsartan as a result of hyperkalemia. It is possible that long-term treatment with an angiotensin II receptor blocker, valsartan, is effective at retarding the deterioration of renal function in patients with nondiabetic renal disease by a mechanism independent of blood pressure reduction.
Similar content being viewed by others
Article PDF
References
Hostetter TH, Olson JL, Rennke HG, Venkatachalam MA, Brenner BM : Hyperfiltration in remnant nephrons: a potentially adverse response to renal ablation. Am J Physiol 1981; 241: F85–F93.
Brenner BM, Lawler EV, Mackenzie HS : The hyperfiltration theory: a paradigm shift in nephrology. Kidney Int 1996; 49: 1774–1777.
Romero JC, Ruilope LM, Bentley MD, Fiksen-Olsen MJ, Lahera V, Vidal MJ : Comparison of the effects of calcium antagonists and converting enzyme inhibitors on renal function under normal and hypertensive conditions. Am J Cardiol 1988; 62: 59G–68G.
Carmines PK, Mitchell KD, Navar LG : Effects of calcium antagonists on renal hemodynamics and glomerular function. Kidney Int Suppl 1992; 36: S43–S48.
Raij L : Recommendations for the management of special populations: renal disease in diabetes. Am J Hypertens 2003; 16: 46S–49S.
Parving HH, Andersen S, Jacobsen P, et al: Angiotensin receptor blockers in diabetic nephropathy: renal and cardiovascular end points. Semin Nephrol 2004; 24: 147–157.
Jafar TH, Schmid CH, Landa M, et al: Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data. Ann Intern Med 2001; 135: 73–87.
Wolf G : Angiotensin II as a mediator of tubulointerstitial injury. Nephrol Dial Transplant 2000; 15 ( Suppl 6): 61–63.
Luft FC : Proinflammatory effects of angiotensin II and endothelin: targets for progression of cardiovascular and renal diseases. Curr Opin Nephrol Hypertens 2002; 11: 59–66.
Juknevicius I, Segal Y, Kren S, Lee R, Hostetter TH : Effect of aldosterone on renal transforming growth factor-beta. Am J Physiol Renal Physiol 2004; 286: F1059–F1062.
Hostetter TH, Ibrahim HN : Aldosterone in chronic kidney and cardiac disease. J Am Soc Nephrol 2003; 14: 2395–2401.
Brewster UC, Perazella MA : The renin-angiotensin-aldosterone system and the kidney: effects on kidney disease. Am J Med 2004; 116: 263–272.
Durvasula RV, Petermann AT, Hiromura K, et al: Activation of a local tissue angiotensin system in podocytes by mechanical strain. Kidney Int 2004; 65: 30–39.
Mifsud SA, Allen TJ, Bertram JF, et al: Podocyte foot process broadening in experimental diabetic nephropathy: amelioration with renin-angiotensin blockade. Diabetologia 2001; 44: 878–882.
Davis BJ, Cao Z, de Gasparo M, Kawachi H, Cooper ME, Allen TJ : Disparate effects of angiotensin II antagonists and calcium channel blockers on albuminuria in experimental diabetes and hypertension: potential role of nephrin. J Hypertens 2003; 21: 209–216.
Lewis EJ, Hunsicker LG, Bain RP, Rohde RD : The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993; 329: 1456–1462.
Brenner BM, Cooper ME, de Zeeuw D, et al: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861–869.
Lewis EJ, Hunsicker LG, Clarke WR, et al: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345: 851–860.
Maschio G, Alberti D, Janin G, et al: Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. N Engl J Med 1996; 334: 939–945.
Ruggenenti P : Angiotensin-converting enzyme inhibition and angiotensin II antagonism in nondiabetic chronic nephropathies. Semin Nephrol 2004; 24: 158–167.
Iino Y, Hayashi M, Kawamura T, et al: Renoprotective effect of losartan in comparison to amlodipine in patients with chronic kidney disease and hypertension—a report of the Japanese Losartan Therapy Intended for the Global Renal Protection in Hypertensive Patients (JLIGHT) study. Hypertens Res 2004; 27: 21–30.
Peterson JC, Adler S, Burkart JM, et al: Blood pressure control, proteinuria, and the progression of renal disease. The Modification of Diet in Renal Disease Study. Ann Intern Med 1995; 123: 754–762.
Remuzzi G, Chiurchiu C, Ruggenenti P : Proteinuria predicting outcome in renal disease: nondiabetic nephropathies (REIN). Kidney Int Suppl 2004; 92: S90–S96.
Abbate M, Benigni A, Bertani T, Remuzzi G : Nephrotoxicity of increased glomerular protein traffic. Nephrol Dial Transplant 1999; 14: 304–312.
Abbate M, Zoja C, Morigi M, et al: Transforming growth factor-beta1 is up-regulated by podocytes in response to excess intraglomerular passage of proteins: a central pathway in progressive glomerulosclerosis. Am J Pathol 2002; 161: 2179–2193.
Kannel WB, Stampfer MJ, Castelli WP, Verter J : The prognostic significance of proteinuria: the Framingham study. Am Heart J 1984; 108: 1347–1352.
Culleton BF, Larson MG, Parfrey PS, Kannel WB, Levy D : Proteinuria as a risk factor for cardiovascular disease and mortality in older people: a prospective study. Am J Med 2000; 109: 1–8.
Dykeman-Sharpe J : Proteinuria, a modifiable risk factor: angiotensin converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs). CANNT J 2003; 13: 34–38.
Chobanian AV, Bakris GL, Black HR, et al: The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289: 2560–2572.
European Society of Hypertension-European Society of Cardiology Guidelines Committee : 2003 European Society of Hypertension–European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003; 21: 1011–1153.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Ishimitsu, T., Kameda, T., Akashiba, A. et al. Effects of Valsartan on the Progression of Chronic Renal Insufficiency in Patients with Nondiabetic Renal Diseases. Hypertens Res 28, 865–870 (2005). https://doi.org/10.1291/hypres.28.865
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1291/hypres.28.865
Keywords
This article is cited by
-
The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2019)
Hypertension Research (2019)
-
RAGE-aptamer attenuates deoxycorticosterone acetate/salt-induced renal injury in mice
Scientific Reports (2018)